1 de KeyserJ, SulterG, LuitenP G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? [J]. Trends Neurosci, 1999, 22(12): 535-540.
2 ChenH F, PanX L, WangJ W, et al. Protein-drug interactome analysis of SSRI-mediated neurorecovery following stroke [J]. Biosystems, 2014, 120: 1-9.
3 RueterL E, FornalC A, JacobsB L. A critical review of 5-HT brain microdialysis and behavior [J]. Rev Neurosci, 1997, 8(2): 117-137.
4 MostertJ P, KochM W, HeeringsM, et al. Therapeutic potential of fluoxetine in neurological disorders [J]. Cns Neurosci Ther, 2008, 14(2): 153-164.
5 HackettM L, PicklesK. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies [J]. Int J Stroke, 2014, 9(8): 1017-1025.
6 FlasterM, SharmaA, RaoM. Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery [J]. Top Stroke Rehabil, 2013, 20(2): 139-150.
7 ParienteJ, LoubinouxI, CarelC, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke [J]. Ann Neurol, 2001, 50(6): 718-729.
8 PaolucciS, AntonucciG, GrassoM G, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study [J]. Cerebrovasc Dis, 2001, 12(3): 264-271.
9 CholletF, TardyJ, AlbucherJ F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial [J]. Lancet Neurol, 2011, 10(2): 123-130.
10 MeadG E, HsiehC F, LeeR, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery [J]. Cochrane Database Syst Rev, 2012, 11: CD009286.
11 RobinsonR G, SchultzS K, CastilloC, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study [J]. Am J Psychiatry, 2000, 157(3): 351-359.
12 PlegerB, SchwenkreisP, GrunbergC, et al. Fluoxetine facilitates use-dependent excitability of human primary motor cortex [J]. Clin Neurophysiol, 2004, 115(9): 2157-2163.
13 NannettiL, PaciM, PasquiniJ, et al. Motor and functional recovery in patients with post-stroke depression [J]. Disabil Rehabil, 2005, 27(4): 170-175.
14 GonzenbachR R, TaegtmeyerA B, LuftA, et al. Fluoxetine and motor recovery after ischaemic stroke [J]. Lancet Neurol, 2011, 10(6): 499-500.
15 ShinT K, KangM S, LeeH Y, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice [J]. Korean J Physiol Pharmacol, 2009, 13(3): 257-263.
16 LimC M, KimS W, ParkJ Y, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect [J]. J Neurosci Res, 2009, 87(4): 1037-1045.
17 NgK L, GibsonE M, HubbardR, et al. Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model [J]. Stroke, 2015, 46(10): 2951-2960.
18 ZhuB G, SunY, SunZ Q, et al. Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke [J]. CNS Neurosci Ther, 2012, 18(7): 530-535.
19 LoubinouxI, TombariD, ParienteJ, et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer [J]. Neuroimage, 2005, 27(2): 299-313.
20 Gerdelat-MasA, LoubinouxI, TombariD, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects [J]. Neuroimage, 2005, 27(2): 314-322.
21 BerendsH I, NijlantJ, van PuttenM, et al. Single dose of fluoxetine increases muscle activation in chronic stroke patients [J]. Clin Neuropharmacol, 2009, 32(1): 1-5.
22 QiaoJ, WangJ, WangH, et al. Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model [J]. Glia, 2016, 64(2): 240-254.
23 ShanH, BianY, ShuZ, et al. Fluoxetine protects against IL-1beta-induced neuronal apoptosis via downregulation of p53 [J]. Neuropharmacology, 2016, 107: 68-78.
24 SiepmannT, PenzlinA I, KepplingerJ, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence [J]. Brain Behav, 2015, 5(10): e00373.
25 TiradentesR V, PiresJ G, SilvaN F, et al. Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity [J]. Braz J Med Biol Res, 2014, 47(7): 554-559.
26 GreeneJ, BanasrM, LeeB, et al. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization [J]. Neuropsychopharmacology, 2009, 34(11): 2459-2468.
27 TakebayashiM, HashimotoR, HisaokaK, et al. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders [J]. J Neural Transm (Vienna), 2010, 117(9): 1119-1122.
28 SchmidtH D, DumanR S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior [J]. Behav Pharmacol, 2007, 18(5-6): 391-418.
29 DempseyR J, SailorK A, BowenK K, et al. Stroke-induced progenitor cell proliferation in adult spontaneously hypertensive rat brain: effect of exogenous IGF-1 and GDNF [J]. J Neurochem, 2003, 87(3): 586-597.
30 WiltroutC, LangB, YanY, et al. Repairing brain after stroke: a review on post-ischemic neurogenesis [J]. Neurochem Int, 2007, 50(7-8): 1028-1041.
31 TiraboschiE, TarditoD, KasaharaJ, et al. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades [J]. Neuropsychopharmacology, 2004, 29(10): 1831-1840.
32 LonzeB E, GintyD D. Function and regulation of CREB family transcription factors in the nervous system [J]. Neuron, 2002, 35(4): 605-623.
33 MercierG, LennonA M, RenoufB, et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes [J]. J Mol Neurosci, 2004, 24(2): 207-216.
34 RiefW, BarskyA J, BingelU, et al. Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions [J]. Neurosci Biobehav Rev, 2016, 60: 51-64.
35 OfekK, SchoknechtK, Melamed-BookN, et al. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling [J]. J Cell Mol Med, 2012, 16(11): 2736-2744.
36 KhodanovichM, KiselA, KudabaevaM, et al. Effects of fluoxetine on hippocampal neurogenesis and neuroprotection in the model of global cerebral ischemia in rats [J]. Int J Mol Sci, 2018. DOI： info:doi/10.3390/ijms19010162.
37 SinghD P, ChopraK. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke [J]. Pharmacol Biochem Behav, 2014, 120: 33-42.
38 DhamiK S, ChurchwardM A, BakerG B, et al. Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult [J]. Mol Cell Neurosci, 2013, 56: 365-374.
39 LiW L, CaiH H, WangB, et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke [J]. J Neurosci Res, 2009, 87(1): 112-122.
40 ArvidssonA, CollinT, KirikD, et al. Neuronal replacement from endogenous precursors in the adult brain after stroke [J]. Nat Med, 2002, 8(9): 963-970.
41 VaswaniM, LindaF K, RameshS. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27(1): 85-102.
42 SunX, SunX, LiuT, et al. Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats [J]. Neurosci Lett, 2015, 603: 31-36.
43 OhabJ J, FlemingS, BleschA, et al. A neurovascular niche for neurogenesis after stroke [J]. J Neurosci, 2006, 26(50): 13007-13016.
44 SunY, SunX, QuH, et al. Neuroplasticity and behavioral effects of fluoxetine after experimental stroke [J]. Restor Neurol Neurosci, 2017, 35(5): 457-468.
45 CorbettA M, SieberS, WyattN, et al. Increasing neurogenesis with fluoxetine, simvastatin and ascorbic acid leads to functional recovery in ischemic stroke [J]. Recent Pat Drug Deliv Formul, 2015, 9(2): 158-166.
46 PengL, GuL, LiB, et al. Fluoxetine and all other SSRIs are 5-HT2B agonists － Importance for their therapeutic effects [J]. Curr Neuropharmacol, 2014, 12(4): 365-379.
47 HertzL, RothmanD L, LiB, et al. Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift [J]. Front Behav Neurosci, 2015, 9: 25.
48 DiazS L, Narboux-NemeN, BoutourlinskyK, et al. Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants [J]. Eur Neuropsychopharmacol, 2016, 26(2): 265-279.
49 WindleV, CorbettD. Fluoxetine and recovery of motor function after focal ischemia in rats [J]. Brain Res, 2005, 1044(1): 25-32.
50 ZhaoC S, PuurunenK, SchallertT, et al. Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury [J]. Behav Brain Res, 2005, 158(2): 211-220.
51 WangM T, ChuC L, YehC B, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study [J]. J Clin Psychiatry, 2015, 76(7): e877-e885.
52 HeY, CaiZ, ZengS, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study [J]. Clin Neurol Neurosurg, 2018, 168: 1-6.
53 MortensenJ K, LarssonH, JohnsenS P, et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study [J]. Stroke, 2013, 44(2): 420-426.
54 PintoC B, Saleh VelezF G, LopesF, et al. SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus [J]. Front Neurosci, 2017, 11: 637.
55 AlperK, SchwartzK A, KoltsR L, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports [J]. Biol Psychiatry, 2007, 62(4): 345-354.
56 LiepertJ. Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation [J]. Curr Opin Neurol, 2016, 29(6): 700-705.
57 FoltinR W, HaneyM, ComerS D, et al. Effect of fluoxetine on food intake of humans living in a residential laboratory [J]. Appetite, 1996, 27(2): 165-181.
58 RieckmannN, KronishI M, ShapiroP A, et al. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study [J]. JAMA Intern Med, 2013, 173(12): 1150-1151.
59 GrahamC, LewisS, ForbesJ, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis [J]. Trials, 2017, 18(1): 627.
